Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center, New York
ir dar 1

Renkami dalyviai1/2 fazė

Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-28 · NCT06773195

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Memorial Sloan Kettering Cancer Center, New York
Mount Sinai School of Medicine, New York
Weill Cornell Medicine, New York

Renkami dalyviai1 fazė

Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-22 · NCT07441694

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

Wilmot Cancer Institute, University of Rochester, Rochester

Renkami dalyviaiAnkstyvoji 1 fazė

Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-06-03 · NCT03964506

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Roswell Park Cancer Institute, Buffalo
Ruttenberg Treatment Center, New York
Memorial Sloan Kettering Cancer Center, New York
ir dar 1

Renkami dalyviai2 fazė

Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-06 · NCT05835466

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

GSK Investigational Site, New York

Renkami dalyviai2 fazė

Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-20 · NCT06517875

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Icahn School of Medicine At Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York

Renkami dalyviai1 fazė

Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-17 · NCT06034002

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Memorial Sloan Kettering, New York

Renkami dalyviai2 fazė

Amžius nuo 18 iki 66 · Visoms lytims · Atnaujinta 2026-03-17 · NCT06859424

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Weill Cornell Medicine NewYork-Presbyterian, New York

Renkami dalyviai2 fazė

Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-12 · NCT05980806

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Memorial Sloan Kettering Cancer Center, New York

Renkami dalyviaiStebimasis tyrimas

Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-01-23 · NCT07362225

MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial

Ruttenberg Treatment Center, New York

Renkami dalyviai2 fazė

Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-12-17 · NCT06541249

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Buffalo
Massive Bio SYNERGY-AI site, Hempstead
Massive Bio SYNERGY-AI site, Manhasset
ir dar 2

Renkami dalyviaiStebimasis tyrimas

Visi amžiai · Visoms lytims · Atnaujinta 2025-10-28 · NCT03452774

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Brookdale University Hospital and Medical Center, Brooklyn
Cayuga Cancer Center, Ithaca
Northwell Health, R.J. Zuckerberg Cancer Center, Lake Success
ir dar 2

Renkami dalyviai3 fazė

Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-25 · NCT06479135

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Columbia University, New York
Montefiore Einstein Cancer Center, The Bronx

Renkami dalyviai1 fazė

Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-04-13 · NCT05423691

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.